EUVIMEDEUVIMED entdecken
Crossref

Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer

Andreia Zuckschwerdt, Pedro França, Tânia Nascimento

Proceedings of Research and Practice in Allied and Environmental Health · 28.08.2026

DOI: 10.26537/prpaeh.v3i2.6127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of Research and Practice in Allied and Environmental Health, erschienen am 28.08.2026. Verfasst von Andreia Zuckschwerdt und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and is often associated with risk factors such as smoking, exposure to carcinogens, and genetic predisposition. Immunotherapy, particularly Pembrolizumab, has revolutionized NSCLC treatment by enhancing the immune response against tumor cells (1–3). The doses to be administered during treatment can be fixed doses or doses based on the patient's weight (4).

Objective

To compare the efficacy and costs associated with fixed-dose (FD) versus weight-based dosing (WBD) of Pembrolizumab in NSCLC treatment.

Methods

A literature review was conducted using PubMed and Elsevier databases, analyzing clinical and economic studies focusing on efficacy, safety, and cost of fixed-dose versus weight-based dosing regimens. Additionally, annual Pembrolizumab consumption at the Unidade Local de Saúde do Algarve (ULSALG) between October 2023 and October 2024 was evaluated, considering associated costs and simulating potential expenses with a WBD regimen, since the current regimen is a fixed dose.

Results

We analyzed 6 original studies focused on clinical efficacy, safety and costs associated with the two posological regimens of Pembrolizumab. Both regimens showed similar efficacy and safety profiles. but highlight economic advantages associated with WBD, especially in patients outside the standard weight range (50-100 kg). The FD regimen, on the other hand, simplifies logistics and minimizes dosage errors, making it widely adopted. Hospital data from ULSALG indicated a higher resource utilization with the fixed-dose regimen. When simulating weight-based dosing based on an average weight of 70 kg, the analysis suggested a reduction in resource consumption. The economic analysis at ULSALG demonstrates significant cost savings with WBD. Additionally, strategies such as vial sharing could further enhance economic efficiency.

Conclusion

The choice between FD and WBD requires careful consideration of patient characteristics and the administration context. Future studies should further explore the large-scale implementation impact of weight-based dosing.

Schlagwörter

pembrolizumabnon-small cell lung cancerweight-based dosingfixed-dose regimenimmunotherapytreatment cost comparisonresource utilization (health care)drug useAlgarve

Zitieren

APA

Zuckschwerdt, A., França, P., & Nascimento, T. (2026). Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer. Proceedings of Research and Practice in Allied and Environmental Health. https://doi.org/10.26537/prpaeh.v3i2.6127

Vancouver

Zuckschwerdt A, França P, Nascimento T. Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer. Proceedings of Research and Practice in Allied and Environmental Health. 2026. doi:10.26537/prpaeh.v3i2.6127

BibTeX
@article{Zuckschwerdt2026,
  author = {Zuckschwerdt, Andreia and França, Pedro and Nascimento, Tânia},
  title = {Pembrolizumab: Comparison Between Fixed Dose and Weight-Based Dose in the Treatment of Non-Small Cell Lung Cancer},
  journal = {Proceedings of Research and Practice in Allied and Environmental Health},
  year = {2026},
  doi = {10.26537/prpaeh.v3i2.6127}
}
Kostenlos starten →